Get the Stockscreener App
23.98
3.00%
0.825
Tandem Diabetes Care Inc stock is traded at $23.98, with a volume of 57,189.
It is up +3.00% in the last 24 hours and up +13.98% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$23.15
Open:
$23.27
24h Volume:
57,189
Relative Volume:
0.03
Market Cap:
$1.62B
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-11.47
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
+5.93%
1M Performance:
+13.98%
6M Performance:
+42.10%
1Y Performance:
-36.17%
1-Day Range:
$23.21
$23.95
1-Week Range:
$21.35
$23.95
52-Week Range:
$9.98
$38.18
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
23.84 | 1.57B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
128.65 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.42 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
356.74 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.80 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.72 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-21-25 | Resumed | Stifel | Hold |
| Sep-08-25 | Initiated | Oppenheimer | Outperform |
| Aug-12-25 | Upgrade | Citigroup | Sell → Neutral |
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Will Tandem Diabetes Care Inc. stock benefit from infrastructure spending2026 world cup usa national team round of 16 goalkeepers low block defense winner prediction guide - Улправда
Positive changes ahead for diabetes in 2026 - BioWorld MedTech
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - The Globe and Mail
Disposable Insulin Pumps Market is expected to reach US$ 6.9 - openPR.com
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - PR Newswire
Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules - TipRanks
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Favourable Signals For Tandem Diabetes Care: Numerous Insiders Acquired Stock - 富途牛牛
ROSEN, LEADING INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE - GlobeNewswire Inc.
HEDIS Glycemic Goal Achieved Using Control-IQ Technology - The American Journal of Managed Care® (AJMC®)
Is Tandem Diabetes Care (TNDM) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance
What Tandem Diabetes Care (TNDM)'s Canadian Smartphone Bolus Launch Means For Shareholders - Yahoo Finance
Tandem Diabetes Care (FRA:TD5A) EV-to-OCF : -179.84 (As of Dec. 25, 2025) - GuruFocus
Should Tandem’s Canadian Smartphone Bolus Launch Reshape How Investors View TNDM’s Connected-Care Strategy? - Sahm
Insulin Delivery Devices Market Outlook: Market to Reach US$ - openPR.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Artificial Pancreas System Market is set for steady growth to US$ - openPR.com
Price-Driven Insight from (TNDM) for Rule-Based Strategy - news.stocktradersdaily.com
Clinical ink announces collaboration with Tandem Diabetes Care to integrate Automated Insulin Delivery data into the GlucoseReady™ connected device software platform - PRWeb
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Gainers Report: Why Tandem Diabetes Care Inc. (TD5A) stock could break out in 2025Trade Risk Assessment & Verified Momentum Stock Watchlist - Улправда
Why Tandem Diabetes Care Inc. (TD5A) stock is a strong analyst pickQuarterly Trade Review & AI Enhanced Trading Alerts - Улправда
Will Tandem Diabetes Care Inc. (TD5A) stock beat value stocksJuly 2025 Snapshot & Fast Gain Stock Trading Tips - Улправда
Taking Stock of Tandem Diabetes Care (TNDM) After t:slim App Launch and Rising Growth Optimism - Sahm
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Book value per share of Tandem Diabetes Care, Inc. – SWB:TD5A - TradingView — Track All Markets
Stock Analysis: Will Tandem Diabetes Care Inc. stock split again soonWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - Улправда
How interest rate cuts could boost Tandem Diabetes Care Inc. stock2025 Breakouts & Breakdowns & Weekly High Return Forecasts - DonanımHaber
What risks investors should watch in Tandem Diabetes Care Inc. stockJuly 2025 Highlights & Reliable Breakout Stock Forecasts - Улправда
Is Tandem Diabetes Care Inc. stock oversold or undervaluedMarket Performance Recap & Community Verified Trade Signals - DonanımHaber
Q3 2025 Healthcare Technology Earnings Review: Revenue Beats & Stock PerformanceNews and Statistics - IndexBox
How resilient is Tandem Diabetes Care Inc. stock in market downturnsJuly 2025 Volume & Real-Time Market Sentiment Alerts - DonanımHaber
Will Tandem Diabetes Care Inc. stock deliver better than expected guidanceWeekly Investment Recap & Community Driven Trade Alerts - ulpravda.ru
Unpacking Q3 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks - Yahoo Finance
What makes Tandem Diabetes Care Inc. (TD5A) stock appealing to growth investorsWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
TNDM Sees Analyst Rating Maintain and Price Target Rise by Truis - GuruFocus
Truist Securities Adjusts Price Target on Tandem Diabetes Care to $24 From $17, Maintains Hold Rating - marketscreener.com
Tandem t:slim Mobile App Now Available in Canada - Business Wire
Bank Watch: Will Tandem Diabetes Care Inc. (TD5A) stock beat value stocksQuarterly Portfolio Summary & Accurate Trade Setup Notifications - Улправда
The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Mobi-T Pump And App MilestonesLearn Why - Sahm
Mizuho Maintains Tandem Diabetes Care (TNDM) Neutral Recommendation - Nasdaq
Tandem Diabetes (TNDM) EVP reports RSU vesting and updated holdings - Stock Titan
RBC Adjusts Price Target on Tandem Diabetes Care to $30 From $25, Maintains Outperform Rating - marketscreener.com
TNDM: Mizuho Raises Price Target for Tandem Diabetes Care | TNDM Stock News - GuruFocus
Baird upgrades Tandem Diabetes Care stock rating to Outperform on Mobi-T launch - Investing.com Canada
Tandem Diabetes Care Shares Rise After Baird Upgrade - marketscreener.com
Tandem Diabetes (TNDM) Upgraded by Baird Amid MedTech Sector Out - GuruFocus
Tandem upgraded, Zimmer, ResMed downgraded at Baird (TNDM) - Seeking Alpha
Baird Upgrades Tandem Diabetes Care to Outperform From Neutral, Adjusts PT to $30 From $18 - marketscreener.com
TNDM Stock Sees 66.67% Price Target Increase with Outperform Rat - GuruFocus
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):